tert-butyl (3S)-3-amino-3-(6-methoxypyridin-3-yl)propanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (3S)-3-amino-3-(6-methoxypyridin-3-yl)propanoate
• 化学式: C₁₃H₂₀N₂O₃
• 分子量: 252.313
• InChiKey: UDJZWJOZOFWUFK-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  74.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-甲氧基吡啶 在 palladium diacetate 、 palladium dihydroxide N-甲基吡咯烷酮 、 正丁基锂 、 氢气 、 溴 、 sodium acetate 、 溶剂黄146 、 三乙胺 、 三(邻甲基苯基)磷 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 、 二氯甲烷 、 水 为溶剂， -65.0~90.0 ℃ 、275.79 kPa 条件下， 反应 37.0h， 生成 tert-butyl (3S)-3-amino-3-(6-methoxypyridin-3-yl)propanoate
  参考文献：
  名称：

  An Efficient Synthesis of an α_vβ₃ Antagonist

  摘要：

  A practical preparation of an alpha(v)beta(3) antagonist is reported. The antagonist consists of three key components, a tetrahydronaphthyridine moiety, a beta-alanine moiety, and a central imidazolidone moiety. The tetrahydronaphthyridine component was prepared using two different methods, both of which relied on variations of the Friedlander reaction to establish the desired regiochemistry. The beta-alanine component was prepared using Davies' asymmetric 1,4-addition methodology as the key stereo-defining step. The central imidazolidone portion was created from these two components using an effective three-step cyclization protocol. Thus, a highly convergent process for the drug candidate was defined.

  DOI：

  10.1021/jo030297u

文献信息

• COMPOSITIONS AND METHODS FOR TREATING CANCER
  申请人：O'NEIL Jennifer

  公开号：US20120289481A1

  公开（公告）日：2012-11-15

  The instant invention provides a method of treating a cancer selected from the group consisting of non-small cell lung cancer and breast cancer with an mTOR inhibitor and an αvβ3 integrin antagonist, wherein the mTOR inhibitor is ridaforolimus, everolimus, temsirolimus or a combination thereof.

  本发明提供了一种使用mTOR抑制剂和αvβ3整合素拮抗剂治疗非小细胞肺癌和乳腺癌的方法，其中mTOR抑制剂为利达伐罗麦、依维莫司、替米罗鲁司或其组合。
• Compositions and Methods for Treating Cancer
  申请人：ARIAD Pharmaceuticals, Inc.

  公开号：US20140349968A1

  公开（公告）日：2014-11-27

  The instant invention provides a method of treating a cancer selected from the group consisting of non-small cell lung cancer and breast cancer with an mTOR inhibitor and an αv62 3 integrin antagonist, wherein the mTOR inhibitor is ridaforolimus, everolimus, temsirolimus or a combination thereof.

  本发明提供了一种治疗非小细胞肺癌和乳腺癌的方法，该方法使用mTOR抑制剂和αv62 3整合素拮抗剂，其中mTOR抑制剂为ridaforolimus、everolimus、temsirolimus或其组合。
• An Efficient Synthesis of an α_vβ₃ Antagonist
  作者：Nobuyoshi Yasuda、Yi Hsiao、Mark S. Jensen、Nelo R. Rivera、Chunhua Yang、Kenneth M. Wells、James Yau、Michael Palucki、Lushi Tan、Peter G. Dormer、Ralph P. Volante、David L. Hughes、Paul J. Reider

  DOI：10.1021/jo030297u

  日期：2004.3.1

  A practical preparation of an alpha(v)beta(3) antagonist is reported. The antagonist consists of three key components, a tetrahydronaphthyridine moiety, a beta-alanine moiety, and a central imidazolidone moiety. The tetrahydronaphthyridine component was prepared using two different methods, both of which relied on variations of the Friedlander reaction to establish the desired regiochemistry. The beta-alanine component was prepared using Davies' asymmetric 1,4-addition methodology as the key stereo-defining step. The central imidazolidone portion was created from these two components using an effective three-step cyclization protocol. Thus, a highly convergent process for the drug candidate was defined.